Pharma Mar Sa

Pharma Mar S.A. markets sea‑derived oncology drugs—Yondelis (sarcoma/ovarian), Aplidin (myeloma), Zepzelca (lung cancer)—and develops RNA‑interference products, positioning itself as a niche leader in Europe, the U.S. and China.

Headquarters: Spain (ESP)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Manufacturing
Industry: Pharmaceutical Manufacturing

Employees: 500
HQ: Madrid

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
PHM	Pharma Mar Sa Cap: 1.4B \| P/E: 40.8	EQUITY	MCE	EUR	ES0169501022	Active	📈